Loading the section…
The price of Ocular Therapeutix, Inc. (OCUL) on October 9, 2026 is 7.54 USD, +0.40% on the day. Over 52 weeks the stock traded between 6.23 USD and 16.44 USD; the price now sits 13% of the way up that range. Over the past year the price changed by -36.69%. Market capitalization is 1.65 billion USD, rank 89 among 372 stocks of the same industry with a known capitalization.
Closing prices for 9 October 2026
Next earnings report: 3 November 2026 · Earnings calendar
Change over the period shown (line colour): −36.37 %
Ocular Therapeutix, Inc. trades on Nasdaq under the ticker OCUL. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks OCUL has traded between 6.23 $ and 16.44 $. As of 9 October 2026 the price stood 12.83 % of the way from the 52-week low to the high.
Over one year OCUL shares fell 36.69 %; over six months they fell 14.22 %. Volatility over 90 days is 66.10 %. Dividends are not included: this is price change only, as of 9 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 31.7, above the sector median of 4.0. Price to book is 2.8, above the sector median of 2.5. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 9 October 2026 | 7.49 | 7.68 | 7.38 | 7.54 | 3M |
| 8 October 2026 | 7.20 | 7.57 | 7.06 | 7.51 | 4M |
| 7 October 2026 | 7.26 | 7.55 | 7.19 | 7.23 | 3M |
| 6 October 2026 | 7.30 | 7.57 | 7.13 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Ocular Therapeutix, Inc. (OCUL) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2026-03-31, revenue was 52.0m $, net income was -290.5m $. Incorporated in US.
This summary is compiled automatically from SEC filings and exchange data.
Address:15 CROSBY DRIVE, BEDFORD, MA, 01730, US
Ocular Therapeutix, Inc. reported revenue of 52M $ and a net loss of 290M $ over the last four quarters. Net margin is −558.24 %. Revenue changed by −12.76 % year over year. Earnings per share are −1.44 $. Market capitalisation is 1.7B $.
OCUL has a return on equity of −49.95 %, below the sector median of −41.68 %. Return on assets is −39.66 %, below the sector median of −32.11 %. Operating margin is −575.43 %, below the sector median of −26.84 %.
| 1.2B |
| PFEPfizer, Inc. | 28.28 | +1.65 % | 922M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 7.34 |
| 3M |
| 5 October 2026 | 6.93 | 7.27 | 6.79 | 7.25 | 6M |
| 2 October 2026 | 7.40 | 7.43 | 6.94 | 6.96 | 5M |
| 1 October 2026 | 7.63 | 7.71 | 7.26 | 7.29 | 5M |
| 30 September 2026 | 7.88 | 8.16 | 7.63 | 7.67 | 5M |
| 29 September 2026 | 7.80 | 8.13 | 7.51 | 7.87 | 5M |
| 28 September 2026 | 9.38 | 9.38 | 7.18 | 7.66 | 15M |
| 25 September 2026 | 9.77 | 9.85 | 9.59 | 9.65 | 2M |
| 24 September 2026 | 9.94 | 9.98 | 9.60 | 9.82 | 2M |
| 23 September 2026 | 10.48 | 10.57 | 9.77 | 10.00 | 2M |
| 22 September 2026 | 10.08 | 10.61 | 10.02 | 10.50 | 2M |
| 21 September 2026 | 10.08 | 10.17 | 9.81 | 9.99 | 2M |
| 18 September 2026 | 10.15 | 10.26 | 9.90 | 9.99 | 4M |
| 17 September 2026 | 10.11 | 10.55 | 10.06 | 10.14 | 2M |
| 16 September 2026 | 10.21 | 10.32 | 9.81 | 9.87 | 3M |
| 15 September 2026 | 10.80 | 10.89 | 10.13 | 10.19 | 2M |
| 14 September 2026 | 10.61 | 10.85 | 10.49 | 10.72 | 2M |